Sequencing-based Counting of Plasma Epstein-Barr Virus DNA in Non-metastatic Nasopharyngeal Carcinoma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorHunan Cancer Hospital
About this trial
The investigators aim to explore a new EBV DNA surveillance method with both high sensitivity and specificity in nasopharyngeal carcinoma (NPC) patients. the investigators aim to conduct plasma EBV DNA counting by next generation sequencing (NGS) in non-metastatic NPC patients on their diagnose, after two cycles of induction chemotherapy (IC), and 4-8 weeks after definitive radiotherapy. The investigators aim to explore whether sequencing-based counting is better than PCR analysis in plasma EBV-DNA surveillance, so as to monitoring tumor responses to treatment and for guiding individualized treatment adaptation in the future.
Eligibility criteria
Qualifiers
Newly diagnosed, pathologically proven World Health Organization (WHO) type II/III untreated NPC;
Non-metastatic NPC (I-IVA, according to the 8th edition of the AJCC/UICC clinical staging system);
Age at diagnosis: over 18 years old;
Eastern Cooperative Oncology Group (ECOG) score: 0-1
Disqualifiers
Receiving surgery, target therapy, and/or immunotherapy during or before induction phase;
Other previous or concurrent malignant tumors, except adequately treated non-melanoma skin cancer, cervical carcinoma in situ, and thyroid papillary cancer;
Pregnant or lactating women (a pregnancy test should be considered for fertile women with an active sex life);
Previously treated with radical radiotherapy (RT), except non-melanoma skin cancers outside intended RT treatment volume;
Trial design
Treatments tested in this trial
- EBV-DNA next generation sequencing
Treatment groups
No treatment groups listed
Sponsors and collaborators
Source ClinicalTrials.gov